KCI Senior Leadership is composed of three scientific Associate Center Directors (ACDs) for Basic Sciences (Dr. Wei-Zen Wei), Clinical Sciences (Dr. Anthony Shields) and Population Sciences (Dr. Terrance Albrecht). A new senior leadership position, Scientific Director of Cores, has been added (Dr. Fred Miller) with responsibility for oversight and scientific leadership for the Cancer Center Cores. They are all supported by an ACD for Research Administration (Ms. Constance Claybaker) and overseen by the Deputy Center Director, Dr. Ann Schwartz. As President, CEO, and Center Director of the Karmanos Cancer Institute, Dr. Gerold Bepler bears ultimate responsibity for the administration and fiscal management of all KCI resources, including budgeting, personnel and faculty appointments, and space and equipment allocations. The primary responsibility of this team lies in ensuring that all of the Center's resources are optimally deployed to enhance the development of outstanding science as well as intra- and inter-programmatic interactions. These broad areas, each composed of more specific interests for investigation, define the role of the Senior Leaders to ensure the successful completion of broader scientific goals of the Institution through an active portfolio of individual Programs. The ACDs, by participating in such strategic committees as the ACD Committee, President's Committee, and Scientific Leadership Council, support ongoing discussions and debates about the allocation of resources. In addition, the scientific ACDs, oversee a discretionary fund of $750,000 annually to support pilot studies, the new post-doctoral program and recruitment opportunities during the year. Support is requested for Senior Leadership: Dr. Bepler (50% effort, 25% funding), Dr. A. Schwartz (25% effort, 10% funding), Dr. Wei (10% effort and funding), Dr. Shields (10% effort and funding), Dr. Albrecht (10% effort and funding), Ms. Claybaker (10% effort and funding) and Dr. F. Miller (25% effort and funding). Two of the scientific ACDs also serve as Program Leaders and funds for those efforts are requested elsewhere as is the funding for Ms. Claybaker as ACD of Research Administration.
Members of Senior Leadership oversee the mission and strategic plans for the KCI scientific community. The team ensures all KCI resources are optimally deployed to enhance the development of outstanding science.
|Hamel, Lauren M; Penner, Louis A; Albrecht, Terrance L et al. (2016) Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control 23:327-337|
|Xie, Yuran; Kim, Na Hyung; Nadithe, Venkatareddy et al. (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120-9|
|Cheriyan, Vino T; Muthu, Magesh; Patel, Ketan et al. (2016) CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget :|
|Moorman, Patricia G; Alberg, Anthony J; Bandera, Elisa V et al. (2016) Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 26:654-62|
|Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881|
|Herroon, Mackenzie Katheryn; Diedrich, Jonathan Driscoll; Podgorski, Izabela (2016) New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells. Front Endocrinol (Lausanne) 7:84|
|Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172|
|Ekanger, Levi A; Polin, Lisa A; Shen, Yimin et al. (2016) Evaluation of Eu(II) -based positive contrast enhancement after intravenous, intraperitoneal, and subcutaneous injections. Contrast Media Mol Imaging 11:299-303|
|Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :|
|Katz, Matthew H G; Shi, Qian; Ahmad, Syed A et al. (2016) Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151:e161137|
Showing the most recent 10 out of 634 publications